163 related articles for article (PubMed ID: 37715730)
21. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
[TBL] [Abstract][Full Text] [Related]
22. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
[TBL] [Abstract][Full Text] [Related]
23. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer.
Fox E; Oliver T; Rowe M; Thomas S; Zakharia Y; Gilman PB; Muller AJ; Prendergast GC
Front Oncol; 2018; 8():370. PubMed ID: 30254983
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
25. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
29. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
[TBL] [Abstract][Full Text] [Related]
31. Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod.
Berrong Z; Mkrtichyan M; Ahmad S; Webb M; Mohamed E; Okoev G; Matevosyan A; Shrimali R; Abu Eid R; Hammond S; Janik JE; Khleif SN
Cancer Immunol Res; 2018 Feb; 6(2):201-208. PubMed ID: 29305519
[TBL] [Abstract][Full Text] [Related]
32. Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors.
Mei KC; Liao YP; Jiang J; Chiang M; Khazaieli M; Liu X; Wang X; Liu Q; Chang CH; Zhang X; Li J; Ji Y; Melano B; Telesca D; Xia T; Meng H; Nel AE
ACS Nano; 2020 Oct; 14(10):13343-13366. PubMed ID: 32940463
[TBL] [Abstract][Full Text] [Related]
33. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas.
Carceller F; Jerome NP; Fowkes LA; Khabra K; Mackinnon A; Bautista F; Marshall LV; Vaidya S; Mandeville H; Morgan V; Leach MO; Koh DM
Pediatr Hematol Oncol; 2019 Mar; 36(2):103-112. PubMed ID: 30978130
[No Abstract] [Full Text] [Related]
34. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Gállego Pérez-Larraya J; Garcia-Moure M; Labiano S; Patiño-García A; Dobbs J; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; Puigdelloses M; Laspidea V; Astigarraga I; Lopez-Ibor B; Cruz O; Oscoz Lizarbe M; Hervas-Stubbs S; Alkorta-Aranburu G; Tamayo I; Tavira B; Hernandez-Alcoceba R; Jones C; Dharmadhikari G; Ruiz-Moreno C; Stunnenberg H; Hulleman E; van der Lugt J; Idoate MÁ; Diez-Valle R; Esparragosa Vázquez I; Villalba M; de Andrea C; Núñez-Córdoba JM; Ewald B; Robbins J; Fueyo J; Gomez-Manzano C; Lang FF; Tejada S; Alonso MM
N Engl J Med; 2022 Jun; 386(26):2471-2481. PubMed ID: 35767439
[TBL] [Abstract][Full Text] [Related]
37. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.
Lukas RV; Juhász C; Wainwright DA; James CD; Kennedy E; Stupp R; Lesniak MS
J Neurooncol; 2019 Jan; 141(1):111-120. PubMed ID: 30415456
[TBL] [Abstract][Full Text] [Related]
38. Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
Vajapeyam S; Brown D; Billups C; Patay Z; Vezina G; Shiroishi MS; Law M; Baxter P; Onar-Thomas A; Fangusaro JR; Dunkel IJ; Poussaint TY
AJNR Am J Neuroradiol; 2020 Apr; 41(4):718-724. PubMed ID: 32241771
[TBL] [Abstract][Full Text] [Related]
39. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
40. Ketogenic diet treatment in diffuse intrinsic pontine glioma in children: Retrospective analysis of feasibility, safety, and survival data.
Perez A; van der Louw E; Nathan J; El-Ayadi M; Golay H; Korff C; Ansari M; Catsman-Berrevoets C; von Bueren AO
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1383. PubMed ID: 33939330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
